NK cell autoreactivity and autoimmune diseases

Frontiers in Immunology

Volumn 5, Issue FEB, 2014, Pages

  Poggi, Alessandro ^a   Zocchi, Maria Raffaella ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Autoimmunity; Autoreactivity; DNAM1; LAIR1; Mesenchymal stromal cells; NK cells; NKG2D; Regulatory NK cells

Indexed keywords

FIBRONECTIN; HLA ANTIGEN CLASS 1; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 12; LAMININ; VITRONECTIN;

AUTOIMMUNE DISEASE; AUTOIMMUNE HEPATITIS; B LYMPHOCYTE; CELL PROLIFERATION; CYTOKINE PRODUCTION; CYTOLYSIS; CYTOTOXICITY; HOMEOSTASIS; HUMAN; IMMUNE RESPONSE; INFLAMMATORY BOWEL DISEASE; INSULIN DEPENDENT DIABETES MELLITUS; LIVER DISEASE; MEMORY T LYMPHOCYTE; MESENCHYMAL STROMA CELL; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; NONHUMAN; PROTEIN EXPRESSION; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SKIN DISEASE; T LYMPHOCYTE;

EID: 84895541185     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00027     Document Type: Review

References (227)

1. Trinchieri G. Biology of natural killer cells. Adv Immunol (1989) 47:187-376. doi: 10.1016/S0065-2776(08)60664-1.
2. Raulet DH. Interplay of natural killer cells and their receptors with the adaptive immune response. Nat Immunol (2004) 5:996-1002. doi:10.1038/ni1114.
3. Lanier LL. NK cell recognition. Annu Rev Immunol (2005) 23:225-74. doi:10.1146/annurev.immunol.23.021704.115526.
4. Bryceson YT, Long EO. Line of attack: NK cell specifity and integration signal. Curr Opin Immunol (2008) 20:344-52. doi:10.1016/j.coi.2008.03.005.
5. Caligiuri MA. Human natural killer cells. Blood (2008) 112:461-9. doi:10.1182/blood-2007-09-077438.
6. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Rev Immunol (2008) 9:503-10. doi:10.1038/ni1582.
7. Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, et al. Innate or adaptive immunity? The example of natural killer cells. Science (2011) 331:44-9. doi:10.1126/science.1198687.
8. Zingoni A, Ardolino M, Santoni A, Cerboni C. NKG2D and DNAM-1 activating receptors and their lignads in NK-T interactions: role in NK cell-mediated negative regulation of T cell responses. Front Immunol (2013) 3:408. doi:10.3389/fimmu.2012.00408.
9. Spaggiari GM, Carosio R, Pende D, Marcenaro S, Rivera P, Zocchi MR, et al. NK cell-mediated lysis of autologous antigen-presenting cells is triggered by the engagement of the phosphatidylinositol 3-kinase upon ligation of the natural cytotoxicity receptors NKp30 and NKp46. Eur J Immunol (2001) 31:1656-65. doi:10.1002/1521-4141(200106)31:6<::AID-IMMU1656>3.0.CO;2-V.
10. Zitvogel L, Terme M, Borg C, Trinchieri G. Dendritic cell-NK cell cross-talk: regulation and physiopathology. Curr Top Microbiol Immunol (2006) 298:157-74.
11. Seaman WE. Natural killer cells and natural killer T cells. Arthritis Rheum (2000) 43:1204-17. doi:10.1002/1529-0131(200006)43:6<::AID-ANR3>3.0.CO;2-I.
12. Van Kaer L. Natural killer T cells as targets for immunotherapy of autoimmune diseases. Immunol Cell Biol (2004) 82:315-22. doi:10.1111/j.0818-9641.2004.01252.x.
13. Bos JD, de Rie MA, Teunissen MB, Piskin G. Psoriasis: dysregulation of innate immunity. Br J Dermatol (2005) 152:1098-107. doi:10.1111/j.1365-2133.2005.06645.x.
14. Zhang C, Zhang J, Tian Z. The regulatory effect of natural killer cells: do "NK-reg cells" exist? Cell Mol Immunol (2006) 3:241-54.
15. Lünemann A, Lünemann JD, Münz C. Regulatory NK-cell functions in inflammation and autoimmunity. Mol Med (2009) 15:352-8. doi:10.2119/molmed.2009.00035.
16. von Bubnoff D, Andrès E, Hentges F, Bieber T, Michel T, Zimmer J. Natural killer cells in atopic and autoimmune diseases of the skin. J Allergy Clin Immunol (2010) 125:60-8. doi:10.1016/j.jaci.2009.11.020.
17. Ahern DJ, Brennan FM. The role of natural killer cells in the pathogenesis of rheumatoid arthritis: major contributors or essential homeostatic modulators? Immunol Lett (2011) 136:115-21. doi:10.1016/j.imlet.2010.11.001.
18. Berzins SP, Smyth MJ, Baxter AG. Presumed guilty: natural killer T cell defects and human disease. Nat Rev Immunol (2011) 11:131-42. doi:10.1038/nri2904.
19. Conigliaro P, Scrivo R, Valesini G, Perricone R. Emerging role for NK cells in the pathogenesis of inflammatory arthropathies. Autoimmun Rev (2011) 10:577-81. doi:10.1016/j.autrev.2011.04.017.
20. Huang Z, Fu B, Zheng SG, Li X, Sun R, Tian Z, et al. Involvement of CD226+ NK cells in immunopathogenesis of systemic lupus erythematosus. J Immunol (2011) 186:3421-31. doi:10.4049/jimmunol.1000569.
21. Tian Z, Gershwin ME, Zhang C. Regulatory NK cells in autoimmune disease. J Autoimmun (2012) 39:206-15. doi:10.1016/j.jaut.2012.05.006.
22. Zakka LR, Fradkov E, Keskin DB, Tabansky I, Stern JN, Ahmed AR. The role of natural killer cells in autoimmune blistering diseases. Autoimmunity (2012) 45:44-54. doi:10.3109/08916934.2011.606446.
23. Chanvillard C, Jacolik RF, Infante-Duarte C, Nayak RC. The role of natural killer cells in multiple sclerosis and their therapeutic implications. Front Immunol (2013) 4:63. doi:10.3389/fimmu.2013.00063.
24. Fogel LA, Yokoyama WM, French AR. Natural killer cells in human autoimmune disorders. Arthritis Res Ther (2013) 15:216. doi:10.1186/ar4232.
25. Kaur G, Trowsdale J, Fugger L. Natural killer cells and their receptors in multiple sclerosis. Brain (2013) 136:2657-76. doi:10.1093/brain/aws159.
26. Moretta A, Bottino C, Vitale M, Pende D, Biassoni R, Mingari MC, et al. Receptors for HLA class-I molecules in human natural killer cells. Annu Rev Immunol (1996) 14:619-48. doi:10.1146/annurev.immunol.14.1.619.
27. Lanier LL. NK cell receptors. Annu Rev Immunol (1998) 16:359-93. doi:10.1146/annurev.immunol.16.1.359.
28. Long EO. Regulation of immune responses through inhibitory receptors. Annu Rev Immunol (1999) 17:875-904. doi:10.1146/annurev.immunol.17.1.875.
29. Kärre K. NK cells, MHC class I molecules and the missing self. Scand J Immunol (2002) 55:221-8. doi:10.1046/j.1365-3083.2002.01053.x.
30. Kärre K. Natural killer cell recognition of missing self. Nat Immunol (2008) 9(5):477-80. doi:10.1038/ni0508-477.
31. Moretta A, Poggi A, Pende D, Tripodi G, Orengo AM, Pella N, et al. CD69-mediated pathway of lymphocyte activation: anti-CD69 monoclonal antibodies trigger the cytolytic activity of different lymphoid effector cells with the exception of cytolytic T lymphocytes expressing T cell receptor alpha/beta. J Exp Med (1991) 174:1393-8. doi:10.1084/jem.174.6.1393.
32. Moretta A, Bottino C, Vitale M, Pende D, Cantoni C, Mingari MC, et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol (2001) 19:197-223. doi:10.1146/annurev.immunol.19.1.197.
33. Champsaur M, Lanier LL. Effect of NKG2D ligand expression on host immune responses. Immunol Rev (2010) 235:267-85. doi:10.1111/j.0105-2896.2010.00893.x.
34. Meyaard L, Adema GJ, Chang C, Woollatt E, Sutherland GR, Lanier LL, et al. LAIR-1, a novel inhibitory receptor expressed on human mononuclear leukocytes. Immunity (1997) 7:283-90. doi:10.1016/S1074-7613(00)80530-0.
35. Waggoner SN, Kumar V. Evolving role of 2B4/CD244 in T and NK cell responses during virus infection. Front Immunol (2012) 3:377. doi:10.3389/fimmu.2012.00377.
36. Meinke S, Watzl C. NK cell cytotoxicity mediated by 2B4 and NTB-A is dependent on SAP acting downstream of receptor phosphorylation. Front Immunol (2013) 4:3. doi:10.3389/fimmu.2013.00003.
37. Chan CJ, Smyth MJ, Martinet L. Molecular mechanisms of natural killer cell activation to cellular stress. Cell Death Diff (2013) 21(1):5-14. doi:10.1038/cdd.2013.26.
38. Flodstrom-Tulberg M, Bryceson YT, Shi F-D, Hoglund P, Ljunggren H-G. Human natural killer cells in human autoimmunity. Curr Opin Immunol (2009) 21:634-40. doi:10.1016/j.coi.2009.09.012.
39. Vitale M, Bottino C, Sivori S, Sanseverino L, Castriconi R, Marcenaro E, et al. NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complex-restricted tumor cell lysis. J Exp Med (1998) 187:2065-72. doi:10.1084/jem.187.12.2065.
40. Ward J, Bonaparte M, Sacks J, Guterman J, Fogli M, Mavilio D, et al. HIV modulates the expression of lignads important in natural killer cell cytotoxicity on infected primary T cell blasts. Blood (2007) 110:1207-14. doi:10.1182/blood-2006-06-028175.
41. Roy S, Barnes PF, Garg A, Wu S, Cosman D, Vankayalapati R. NK cell lyse regulatory T cells that expand in response to an intracellular pathogen. J Immunol (2008) 180:1729-36.
42. Nausch N, Cerwenka A. NKG2D ligands in tumor immunity. Oncogene (2008) 27:5944-58. doi:10.1038/onc.2008.272.
43. Hayday AC. Gammadelta T cells and the lymphoid stress-surveillance response. Immunity (2009) 31:184-96. doi:10.1016/j.immuni.2009.08.006.
44. Van Kaer L, Parekh VV, Wu L. Invariant natural killer T cells: bridging innate and adaptive immunity. Cell Tissue Res (2011) 343:43-55. doi:10.1007/s00441-010-1023-3.
45. Bottino C, Castriconi R, Pende D, Rivera P, Nanni M, Carnemolla B, et al. Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J Exp Med (2003) 198:557-67. doi:10.1084/jem.20030788.
46. Elishmereni M, Levi-Schaffer F. CD48: a co-stimulatory receptor of immunity. Int J Biochem Cell Biol (2011) 43:25-8. doi:10.1016/j.biocel.2010.09.001.
47. Furukawa H, Kitazawa H, Kaneko I, Matsubara M, Nose M, Ono M. Role of 2B4-mediated signals in the pathogenesis of a murine hepatitis model independent of Fas and Valpha14 NKT cells. Immunology (2009) 128:e151-8. doi:10.1111/j.1365-2567.2008.02936.x.
48. Loschko J, Krug A. Antigen delivery to plasmacytoid dendritic cells-induction of tolerance and immunity. Crit Rev Immunol (2012) 32:489-501. doi:10.1615/CritRevImmunol.v32.i6.20.
49. Münz C, Steinman RM, Fujii S. Dendritic cell maturation by innate lymphocytes: coordinated stimulation of innate and adaptive immunity. J Exp Med (2005) 202:203-7. doi:10.1084/jem.20050810.
50. Guerder S, Joncker N, Mahiddine K, Serre L. Dendritic cells in tolerance and autoimmune diabetes. Curr Opin Immunol (2013) 25(6):670-5. doi:10.1016/j.coi.2013.10.004.
51. Galicia G, Gommerman JL. Plasmacytoid dendritic cells and autoimmune inflammation. Biol Chem (2013). doi:10.1515/hsz-2013-0213.
52. Trinchieri G. Immunobiology of interleukin-12. Immunol Res (1998) 17:269-78. doi:10.1007/BF02786451.
53. Carbone E, Terrazzano G, Ruggiero G, Zanzi D, Ottaiano A, Manzo C, et al. Recognition of autologous dendritic cells by human NK cells. Eur J Immunol (1999) 29:4022-9. doi:10.1002/(SICI)1521-4141(199912)29:12<::AID-IMMU4022>3.3.CO;2-F.
54. Ferlazzo G, Tsang ML, Moretta L, Melioli G, Steinman RM, Münz C. Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J Exp Med (2002) 195:343-51. doi:10.1084/jem.20011149.
55. Pende D, Castriconi R, Romagnani P, Spaggiari GM, Marcenaro S, Dondero A, et al. Expression of the DNAM-1 ligands nectin-2 (CD112) and poliovirus receptor (CD115), on dendritic cells: relevance for natural killer-dendritic cell interaction. Blood (2006) 107:2030-6. doi:10.1182/blood-2005-07-2696.
56. Poggi A, Zocchi MR. Antigen presenting cells and stromal cells trigger human natural killer lymphocytes to autoreactivity: evidence for the involvement of natural cytotoxicity receptors (NCR) and NKG2D. Clin Dev Immunol (2006) 13:325-36. doi:10.1080/17402520600578194.
57. Poggi A, Prevosto C, Zancolli M, Canevali P, Musso A, Zocchi MR. NKG2D and natural cytotoxicity receptors are involved in natural killer cell interaction with self-antigen presenting cells and stromal cells. Ann N Y Acad Sci (2007) 1109:47-57. doi:10.1196/annals.1398.007.
58. Poggi A, Zocchi MR. Human natural killer lymphocytes through the engagement of natural cytotoxicity receptors and NKG2D can trigger self-aggression. Autoimmun Rev (2007) 6:295-9. doi:10.1016/j.autrev.2006.07.003.
59. Nedvetzki S, Sowinski S, Eagle RA, Harris J, Vély F, Pende D, et al. Reciprocal regulation of human natural killer cells and macrophages associated with distinct immune synapses. Blood (2007) 109:3776-85. doi:10.1182/blood-2006-10-052977.
60. Springer TA, Dustin ML. Integrin inside-out signaling and the immunological synapse. Curr Opin Cell Biol (2012) 24:107-15. doi:10.1016/j.ceb.2011.10.004.
61. Dustin ML, Springer TA. Role of lymphocyte adhesion receptors in transient interactions and cell locomotion. Annu Rev Immunol (1991) 9:27-66. doi:10.1146/annurev.iy.09.040191.000331.
62. Luo BH, Carman CV, Springer TA. Structural basis of integrin regulation and signaling. Annu Rev Immunol (2007) 25:619-47. doi:10.1146/annurev.immunol.25.022106.141618.
63. Brown AC, Oddos S, Dobbie IM, Alakoskela JM, Parton RM, Eissmann P, et al. Remodelling of cortical actin where lytic granules dock at natural killer cell immune synapses revealed by super-resolution microscopy. PLoS Biol (2011) 9:e1001152. doi:10.1371/journal.pbio.1001152.
64. Herter J, Zarbock A. Integrin regulation during leukocyte recruitment. J Immunol (2013) 190:4451-7. doi:10.4049/jimmunol.1203179.
65. Liang D, Zuo A, Shao H, Born WK, O'Brien RL, Kaplan HJ, et al. IL-23 receptor expression on γδ T cells correlates with their enhancing or suppressive effects on autoreactive T cells in experimental autoimmune uveitis. J Immunol (2013) 191:1118-25. doi:10.4049/jimmunol.1300626.
66. Geremia A, Biancheri P, Allan P, Corazza GR, Di Sabatino A. Innate and adaptive immunity in inflammatory bowel disease. Autoimmun Rev (2014) 13:3-10. doi:10.1016/j.autrev.2013.06.004.
67. Ottaviani C, Nasorri F, Bedini C, de Pità O, Girolomoni G, Cavani A. CD56brightCD16(-) NK cells accumulate in psoriatic skin in response to CXCL10 and CCL5 and exacerbate skin inflammation. Eur J Immunol (2006) 36:118-28. doi:10.1002/eji.200535243.
68. Kaufman G, D'Ovidio R, Kaldawy A, Assy B, Ullmann Y, Etzioni A, et al. An unexpected twist in alopecia areata pathogenesis: are NK cells protective and CD49b+ T cells pathogenic? Exp Dermatol (2010) 19:e347-9. doi:10.1111/j.1600-0625.2010.01106.x.
69. Ito T, Ito N, Saatoff M, Hashizume H, Fukamizu H, Nickoloff BJ, et al. Maintenance of hair follicle immune privilege is linked to prevention of NK cell attack. J Invest Dermatol (2008) 128:1196-206. doi:10.1038/sj.jid.5701183.
70. Batista MD, Ho EL, Kuebler PJ, Milush JM, Lanier LL, Kallas EG, et al. Skewed distribution of natural killer cells in psoriasis skin lesions. Exp Dermatol (2013) 22:64-6. doi:10.1111/exd.12060.
71. McElwee KJ, Gilhar A, Tobin DJ, Ramot Y, Sundberg JP, Nakamura M, et al. What causes alopecia areata? Exp Dermatol (2013) 22:609-26. doi:10.1111/exd.12209.
72. Kowarik MC, Grummel V, Wemlinger S, Buck D, Weber MS, Berthele A, et al. Immune cell subtyping in the cerebrospinal fluid of patients with neurological diseases. J Neurol (2014) 261(1):130-43. doi:10.1007/s00415-013-7145-2.
73. Jiang W, Chai NR, Maric D, Bielekova B. Unexpected role for granzyme K in CD56bright NK cell-mediated immunoregulation of multiple sclerosis. J Immunol (2011) 187:781-90. doi:10.4049/jimmunol.1100789.
74. Martínez-Rodríguez JE, López-Botet M, Munteis E, Rio J, Roquer J, Montalban X, et al. Natural killer cell phenotype and clinical response to interferon-beta therapy in multiple sclerosis. Clin Immunol (2011) 141:348-56. doi:10.1016/j.clim.2011.09.006.
75. Mayo L, Quintana FJ, Weiner HL. The innate immune system in demyelinating disease. Immunol Rev (2012) 248:170-87. doi:10.1111/j.1600-065X.2012.01135.x.
76. Poli A, Kmiecik J, Domingues O, Hentges F, Bléry M, Chekenya M, et al. NK cells in central nervous system disorders. J Immunol (2013) 190:5355-62. doi:10.4049/jimmunol.1203401.
77. Hamann I, Dörr J, Glumm R, Chanvillard C, Janssen A, Millward JM, et al. Characterization of natural killer cells in paired CSF and blood samples during neuroinflammation. J Neuroimmunol (2013) 254:165-9. doi:10.1016/j.jneuroim.2012.08.009.
78. Sanvito L, Tomita A, Chihara N, Okamoto T, Lin Y, Ogawa M, et al. Increase of Ki-67+ natural killer cells in multiple sclerosis patients treated with interferon-β and interferon-β combined with low-dose oral steroids. J Neuroimmunol (2011) 236:111-7. doi:10.1016/j.jneuroim.2011.05.005.
79. Ren J, Feng Z, Lv Z, Chen X, Li J. Natural killer-22 cells in the synovial fluid of patients with rheumatoid arthritis are an innate source of interleukin 22 and tumor necrosis factor-α. J Rheumatol (2011) 38:2112-8. doi:10.3899/jrheum.101377.
80. Saito S, Nakashima A, Myojo-Higuma S, Shiozaki A. The balance between cytotoxic NK cells and regulatory NK cells in human pregnancy. J Reprod Immunol (2008) 77:14-22. doi:10.1016/j.jri.2007.04.007.
81. Villanueva J, Lee S, Giannini EH, Graham TB, Passo MH, Filipovich A, et al. Natural killer cell dysfunction is a distinguishing feature of systemic onset juvenile rheumatoid arthritis and macrophage activation syndrome. Arthritis Res Ther (2005) 7:R30-7. doi:10.1186/ar1551.
82. Dalbeth N, Gundle R, Davies RJ, Lee YC, McMichael AJ, Callan MF. CD56bright NK cells are enriched at inflammatory sites and can engage with monocytes in a reciprocal program of activation. J Immunol (2004) 173:6418-26.
83. Saito S, Murakoshi K, Kotake S, Kamatani N, Tomatsu T. Granzyme B induces apoptosis of chondrocytes with natural killer cell-like cytotoxicity in rheumatoid arthritis. J Rheumatol (2008) 35:1932-43.
84. Nauta AJ, Fibbe WE. Immunomodulatory properties of mesenchymal stromal cells. Blood (2007) 110:3499-506. doi:10.1182/blood-2007-02-069716.
85. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood (2005) 105:1815-22. doi:10.1182/blood-2004-04-1559.
86. Stagg J, Galipeau J. Mechanisms of immune modulation by mesenchymal stromal cells and clinical translation. Curr Mol Med (2013) 13:856-67. doi:10.2174/1566524011313050016.
87. Le Blanc K. Mesenchymal stromal cells: tissue repair and immune modulation. Cytotherapy (2006) 8:559-61. doi:10.1080/14653240601045399.
88. Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, et al. Developmental committee of the european group for blood and marrow transplantation. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet (2008) 371:1579-86. doi:10.1016/S0140-6736(08)60690-X.
89. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol (2008) 8:726-36. doi:10.1038/nri2395.
90. Poggi A, Prevosto C, Massaro AM, Negrini S, Urbani S, Saccardi R, et al. Interaction between human natural killer cells and bone marrow stromal cells induces NK cell triggering. Role of NKp30 and NKG2D receptors. J Immunol (2005) 175:6352-60.
91. Sotiropoulou PA, Perez SA, Gritzapis AD, Baxevanis CN, Papamichail M. Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells (2006) 24:74-85. doi:10.1634/stemcells.2004-0359.
92. Spaggiari GM, Capobianco A, Becchetti S, Mingari MC, Moretta L. Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood (2006) 107:1484-90. doi:10.1182/blood-2005-07-2775.
93. Spaggiari GM, Moretta L. Cellular and molecular interactions of mesenchymal stem cells in innate immunity. Immunol Cell Biol (2013) 91:27-31. doi:10.1038/icb.2012.62.
94. Kim MH, Kitson RP, Albertsson P, Nannmark U, Basse PH, Kuppen PJ, et al. Secreted and membrane-associated matrix metalloproteinases of IL-2-activated NK cells and their inhibitors. J Immunol (2000) 164:5883-9.
95. Albertsson P, Kim MH, Jonges LE, Kitson RP, Kuppen PJ, Johansson BR, et al. Matrix metalloproteinases of human NK cells. In vivo (2000) 14:269-76.
96. Palmieri G, Serra A, De Maria R, Gismondi A, Milella M, Piccoli M, et al. Cross-linking of alpha 4 beta 1 and alpha 5 beta 1 fibronectin receptors enhances natural killer cell cytotoxic activity. J Immunol (1995) 155:5314-22.
97. Gismondi A, Milella M, Palmieri G, Piccoli M, Frati L, Santoni A. Stimulation of protein tyrosine phosphorylation by interaction of NK cells with fibronectin via alpha 4 beta 1 and alpha 5 beta 1. J Immunol (1995) 154:3128-37.
98. Gismondi A, Bisogno L, Mainiero F, Palmieri G, Piccoli M, Frati L, et al. Proline-rich tyrosine kinase-2 activation by beta 1 integrin fibronectin receptor cross-linking and association with paxillin in human natural killer cells. J Immunol (1997) 159:4729-36.
99. Rabinowich H, Lin WC, Amoscato A, Herberman RB, Whiteside TL. Expression of vitronectin receptor on human NK cells and its role in protein phosphorylation, cytokine production, and cell proliferation. J Immunol (1995) 154:1124-35.
100. Piali L, Hammel P, Uherek C, Bachmann F, Gisler RH, Dunon D, et al. CD31/PECAM-1 is a ligand for alpha v beta 3 integrin involved in adhesion of leukocytes to endothelium. J Cell Biol (1995) 130:451-60. doi:10.1083/jcb.130.2.451.
101. Unger ML, Johansson BR, Nannmark U. Migration of IL-2-activated natural killer cells in vitro: influence of extracellular matrix proteins. APMIS (1996) 104:840-7. doi:10.1111/j.1699-0463.1996.tb04950.x.
102. Diao H, Iwabuchi K, Li L, Onoe K, Van Kaer L, Kon S, et al. Osteopontin regulates development and function of invariant natural killer T cells. Proc Natl Acad Sci U S A (2008) 105:15884-9. doi:10.1073/pnas.0806089105.
103. Chung JW, Kim MS, Piao ZH, Jeong M, Yoon SR, Shin N, et al. Osteopontin promotes the development of natural killer cells from hematopoietic stem cells. Stem Cells (2008) 26:2114-23. doi:10.1634/stemcells.2008-0370.
104. Edsparr K, Johansson BR, Goldfarb RH, Basse PH, Nannmark U, Speetjens FM, et al. Human NK cell lines migrate differentially in vitro related to matrix interaction and MMP expression. Immunol Cell Biol (2009) 87:489-95. doi:10.1038/icb.2009.35.
105. Zhang T, Liu S, Yang P, Han C, Wang J, Liu J, et al. Fibronectin maintains survival of mouse natural killer (NK) cells via CD11b/Src/beta-catenin pathway. Blood (2009) 114:4081-8. doi:10.1182/blood-2009-05-21988.
106. Rabinowich H, Lin WC, Manciule M, Herberman RB, Whiteside TL. Induction of protein tyrosine phosphorylation in human natural killer cells by triggering via alpha 4 beta 1 or alpha 5 beta 1 integrins. Blood (1995) 85:1858-64.
107. Li YQ, Kobayashi M, Kuramitsu Y, Yuan L, Matsushita K, Yagita H, et al. Enhancement of lymphokine-activated killer cell activity by fibronectin. J Immunother (1997) 20:123-30. doi:10.1097/00002371-199703000-00004.
108. Albertsson P, Basse PH, Edsparr K, Kim MH, Goldfarb RH, Kitson RP, et al. Differential locomotion of long-and short-term IL-2-activated murine natural killer cells in a model matrix environment. Scand J Immunol (2007) 66:402-9 Erratum in: Scand J Immunol (2007) 66(5):601. Golfarb, RH [corrected to Goldfarb, RH]. doi:10.1111/j.1365-3083.2007.01956.x.
109. Xia S, Guo Z, Yao Y, Xu X, Yi H, Xia D, et al. Liver stroma enhances activation of TLR3-triggered NK cells through fibronectin. Mol Immunol (2008) 45:2831-8. doi:10.1016/j.molimm.2008.01.035.
110. Meyaard L, Hurenkamp J, Clevers H, Lanier LL, Phillips JH. Leukocyte associated Ig-like receptor-1 functions as an inhibitory receptor on cytotoxic T cells. J Immunol (1999) 162:5800-4.
111. Meyaard L. The inhibitory collagen receptor LAIR-1 (CD305). J Leukoc Biol (2008) 83:799-803. doi:10.1189/jlb.0907609.
112. Lebbink RJ, de Ruiter T, Adelmeijer J, Brenkman AB, van Helvoort JM, Koch M, et al. Collagens are functional, high affinity ligands for the inhibitory immune receptor LAIR-1 J. J Exp Med (2006) 203:1419-25. doi:10.1084/jem.20052554.
113. Lebbink RJ, Raynal N, de Ruiter T, Bihan DG, Farndale RW, Meyaard L. Identification of multiple potent binding sites for human leukocyte associated Ig-like receptor LAIR on collagens II and III. Matrix Biol (2009) 28:202-10. doi:10.1016/j.matbio.2009.03.005.
114. Jiang L, Barclay AN. New assay to detect low-affinity interactions and characterization of leukocyte receptors for collagen including leukocyte-associated Ig-like receptor-1 (LAIR-1). Eur J Immunol (2009) 39:1167-75. doi:10.1002/eji.200839188.
115. Tang X, Narayanan S, Peruzzi G, Apara A, Natarajan K, Margulies DH, et al. A single residue, arginine 65, is critical for the functional interaction of leukocyte-associated inhibitory receptor-1 with collagens. J Immunol (2009) 182:5446-52. doi:10.4049/jimmunol.0804052.
116. Poggi A, Pella N, Morelli L, Spada F, Revello V, Sivori S, et al. p40, a novel surface molecule involved in the regulation of the non-major histocompatibility complex-restricted cytolytic activity in humans. Eur J Immunol (1995) 25:369-76. doi:10.1002/eji.1830250210.
117. Poggi A, Tomasello E, Revello V, Nanni L, Costa P, Moretta L. p40 molecule regulates NK cell activation mediated by NK receptors for HLA class I antigens and TCR-mediated triggering of T lymphocytes. Int Immunol (1997) 9:1271-9. doi:10.1093/intimm/9.9.1271.
118. Leibson PJ. The regulation of lymphocyte activation by inhibitory receptors. Curr Opin Immunol (2004) 16:328-36. doi:10.1016/j.coi.2004.03.006.
119. Lebbink RJ, van den Berg MC, de Ruiter T, Raynal N, van Roon JA, Lenting PJ, et al. The soluble leukocyte-associated Ig-like receptor (LAIR)-2 antagonizes the collagen/LAIR-1 inhibitory immune interaction. J Immunol (2008) 180:1662-9.
120. Olde Nordkamp MJ, van Roon JA, Douwes M, de Ruiter T, Urbanus RT, Meyaard L. Enhanced secretion of leukocyte-associated immunoglobulin-like receptor 2 (LAIR-2) and soluble LAIR-1 in rheumatoid arthritis: LAIR-2 is a more efficient antagonist of the LAIR-1-collagen inhibitory interaction than is soluble LAIR-1. Arthritis Rheum (2011) 63:3749-57. doi:10.1002/art.30612.
121. Simone R, Pesce G, Antola P, Merlo DF, Bagnasco M, Saverino D. Serum LAIR-2 is increased in autoimmune thyroid diseases. PLoS One (2013) 8(5):e63282. doi:10.1371/journal.pone.0063282.
122. Merlo A, Tenca C, Fais F, Battini L, Ciccone E, Grossi CE, et al. Inhibitory receptors CD85j, LAIR-1, and CD152 down-regulate immunoglobulin and cytokine production by human B lymphocytes. Clin Diagn Lab Immunol (2005) 12:705-12.
123. van der Vuurst de Vries AR, Clevers H, Logtenberg T, Meyaard L. Leukocyte-associated immunoglobulin-like receptor-1 (LAIR-1) is differentially expressed during human B cell differentiation and inhibits B cell receptor mediated signaling. Eur J Immunol (1999) 29:3160-7. doi:10.1002/(SICI)1521-4141(199910)29:10<::AID-IMMU3160>3.0.CO;2-S.
124. Jansen CA, Cruijsen CW, de Ruiter T, Nanlohy N, Willems N, Janssen-Korpela PL, et al. Regulated expression of the inhibitory receptor LAIR-1 on human peripheral T cells during T cell activation and differentiation. Eur J Immunol (2007) 37:914-24. doi:10.1002/eji.200636678.
125. Poggi A, Tomasello E, Ferrero E, Zocchi MR, Moretta L. p40/LAIR-1 regulates the differentiation of peripheral blood precursors to dendritic cells induced by granulocyte-monocyte colony-stimulating factor. Eur J Immunol (1999) 28:2086-91. doi:10.1002/(SICI)1521-4141(199807)28:07<::AID-IMMU2086>3.0.CO;2-T.
126. Bonaccorsi I, Cantoni C, Carrega P, Oliveri D, Lui G, Conte R, et al. The immune inhibitory receptor LAIR-1 is highly expressed by plasmacytoid dendritic cells and acts complementary with NKp44 to control IFNα production. PLoS One (2010) 30:e15080. doi:10.1371/journal.pone.0015080.
127. Poggi A, Pellegatta F, Leone BE, Moretta L, Zocchi MR. Engagement of the leukocyte associated Ig-like receptor-1 induces programmed cell death and prevents NF-kappaB nuclear translocation in human myeloid leukemias. Eur J Immunol (2000) 30:2751-8. doi:10.1002/1521-4141(200010)30:10<::AID-IMMU2751>3.0.CO;2-L.
128. Zocchi MR, Pellegatta F, Pierri I, Gobbi M, Poggi A. Leukocyte-associated Ig-like receptor-1 prevents granulocyte-monocyte colony stimulating factor-dependent proliferation and Akt1/PKB alpha activation in primary acute myeloid leukemia cells. Eur J Immunol (2001) 31:3667-75. doi:10.1002/1521-4141(200112)31:12<::AID-IMMU3667>3.0.CO;2-G.
129. Poggi A, Catellani S, Bruzzone A, Caligaris-Cappio F, Gobbi M, Zocchi MR. Lack of the leukocyte-associated Ig-like receptor-1 expression in high-risk chronic lymphocytic leukaemia results in the absence of a negative signal regulating kinase activation and cell division. Leukemia (2008) 22:980-8. doi:10.1038/leu.2008.21.
130. Rygiel TP, Stolte EH, de Ruiter T, van de Weijer ML, Meyaard L. Tumor-expressed collagens can modulate immune cell function through the inhibitory collagen receptor LAIR-1. Mol Immunol (2011) 49:402-6. doi:10.1016/j.molimm.2011.09.006.
131. Burns GF, Werkmeister JA, Triglia T. A novel antigenic cell surface protein associated with T200 is involved in the post-activation stage of human NK cell-mediated lysis. J Immunol (1984) 133:1391-6.
132. Colombo BM, Canevali P, Magnani O, Rossi E, Puppo F, Zocchi MR, et al. Defective expression and function of the leukocyte associated Ig-like receptor 1 in B lymphocytes from sistemi lupus erythematosus patients. PLoS One (2012) 7:e31903. doi:10.1371/journal.pone.0031903.
133. Adeegbe DO, Nishikawa H. Natural and induced T regulatory cells in cancer. Front Immunol (2013) 4:190. doi:10.3389/fimmu.2013.00190.
134. Schmitt EG, Williams CB. Generation and function of induced regulatory T cells. Front Immunol (2013) 4:152. doi:10.3389/fimmu.2013.00152.
135. Gianchecchi E, Delfino DV, Fierabracci A. Recent insights into the role of the PD-1/PD-L1 pathway in immunological tolerance and autoimmunity. Autoimmun Rev (2013) 12(11):1091-100. doi:10.1016/j.autrev.2013.05.003.
136. Lehtimäki S, Lahesmaa R. Regulatory T cells control immune responses through their non-redundant tissue specific features. Front Immunol (2013) 4:294. doi:10.3389/fimmu.2013.00294.
137. Tsai S, Santamaria P. MHC class II polymorphisms, autoreactive T-cells, and autoimmunity. Front Immunol (2013) 4:321. doi:10.3389/fimmu.2013.00321.
138. Crome SQ, Lang PA, Lang KS, Ohashi PS. Natural killer cells regulate diverse T cell responses. Trends Immunol (2013) 34:342-9. doi:10.1016/j.it.2013.03.002.
139. Sun H, Sun C, Tian Z, Xiao W. NK cells in immunotolerant organs. Cell Mol Immunol (2013) 10:202-12. doi:10.1038/cmi.2013.9.
140. Deniz G, Erten G, Kücüksezer UC, Kocacik D, Karagiannidis C, Aktas E, et al. Regulatory NK cells suppress antigen-specific T cell responses. J Immunol (2008) 180:850-7.
141. Ehlers M, Papewalis C, Stenzel W, Jacobs B, Meyer KL, Deenen R, et al. Immunoregulatory natural killer cells suppress autoimmunity by down-regulating antigen-specific CD8+ T cells in mice. Endocrinology (2012) 153:4367-79. doi:10.1210/en.2012-1247.
142. Schneidawind D, Pierini A, Negrin RS. Regulatory T cells and natural killer T cells for modulation of GVHD following allogeneic hematopoietic cell transplantation. Blood (2013) 122:3116-21. doi:10.1182/blood-2013-08-453126.
143. Wang F, Jiang W, Zhang C, Tian Z, Zhang J. Human natural killer cells exhibit negative regulatory function by ectopic expression of hFoxp3 gene. Transplantation (2013) 95:1324-30. doi:10.1097/TP.0b013e318290b086.
144. Fu B, Li X, Sun R, Tong X, Ling B, Tian Z, et al. Natural killer cells promote immune tolerance by regulating inflammatory TH17 cells at the human maternal-fetal interface. Proc Natl Acad Sci U S A (2013) 110:E231-40. doi:10.1073/pnas.1206322110.
145. Cooper MA, Fehnunger TA, Turner SC, Chen KS, Ghaheri BA, Ghayur T, et al. Human natural killer cells: a unique innate immunoregulatory role for CD56bright subset. Blood (2001) 97:3146-51. doi:10.1182/blood.V97.10.3146.
146. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med (2000) 342:1350-8. doi:10.1056/NEJM200005043421807.
147. Chen W, Frank ME, Jin W, Wahl SM. TGF-beta released by apoptotic T cells contributes to an immunosuppressive milieu. Immunity (2001) 14:715-25. doi:10.1016/S1074-7613(01)00147-9.
148. Li MO, Wan YY, Sanjabi S, Robertson AK, Flavell RA. Transforming growth factor-β regulation of immune responses. Annu Rev Immunol (2006) 24:99-146. doi:10.1146/annurev.immunol.24.021605.090737.
149. Keskin DB, Allan DS, Rybalov B, Andzelm MM, Stern JN, Kopcow HD, et al. TGFbeta promotes conversion of CD16+ peripheral blood NK cells into CD16-NK cells with similarities to decidual NK cells. Proc Natl Acad Sci U S A (2007) 104:3378-83. doi:10.1073/pnas.0611098104.
150. Spaggiari GM, Contini P, Carosio R, Arvigo M, Ghio M, Oddone D, et al. Soluble HLA class I molecules induce natural killer cell apoptosis through the engagement of CD8: evidence for a negative regulation exerted by members of the inhibitory receptor superfamily. Blood (2002) 99:1706-14. doi:10.1182/blood.V99.5.1706.
151. Spaggiari GM, Contini P, Dondero A, Carosio R, Puppo F, Indiveri F, et al. Soluble HLA class I induces NK cell apoptosis upon the engagement of killer-activating HLA class I receptors through FasL-Fas interaction. Blood (2002) 100:4098-107. doi:10.1182/blood-2002-04-1284.
152. Ghio M, Contini P, Negrini S, Boero S, Musso A, Poggi A. Soluble HLA-I-mediated secretion of TGF-β1 by human NK cells and consequent down-regulation of anti-tumor cytolytic activity. Eur J Immunol (2009) 39:3459-68. doi:10.1002/eji.200939728.
153. Hayakawa Y, Smyth MJ. CD27 dissects mature NK cells into two subsets with distinct responsiveness and migratory capacity. J Immunol (2006) 176:1517-24.
154. Fu B, Wang F, Sun R, Ling B, Tian Z, Wei H. CD11b and CD27 reflect distinct population and functional specialization in human natural killer cells. Immunology (2011) 133:350-9. doi:10.1111/j.1365-2567.2011.03446.x.
155. Koopman LA, Kopcow HD, Rybalov B, Boyson JE, Orange JS, Schatz F, et al. Human decidual natural killer cells are a unique NK cell subset with immunomodulatory potential. J Exp Med (2003) 198:1201-12. doi:10.1084/jem.20030305.
156. Deniz G, van de Veen W, Akdis M. Natural killer cells in patients with allergic diseases. J Allergy Clin Immunol (2013) 132:527-35. doi:10.1016/j.jaci.2013.07.030.
157. Fuchs A, Vermi W, Lee JS, Lonardi S, Gilfillan S, Newberry RD, et al. Intraepithelial type 1 innate lymphoid cells are a unique subset of IL-12-and IL-15-responsive IFN-γ-producing cells. Immunity (2013) 38:769-81. doi:10.1016/j.immuni.2013.02.010.
158. Sciumé G, Hirahara K, Takahashi H, Laurence A, Villarino AV, Singleton KL, et al. Distinct requirements for T-bet in gut innate lymphoid cells. J Exp Med (2012) 209:2331-8. doi:10.1084/jem.20122097.
159. Cella M, Fuchs A, Vermi W, Facchetti F, Otero K, Lennerz JK, et al. A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity. Nature (2009) 457:722-5. doi:10.1038/nature07537.
160. Fuchs A, Colonna M. Innate lymphoid cells in homeostasis, infection, chronic inflammation and tumors of the gastrointestinal tract. Curr Opin Gastroenterol (2013) 29:581-7. doi:10.1097/MOG.0b013e328365d339.
161. Wei H, Zhang J, Xiao W, Feng J, Sun R, Tian Z. Involvement of human natural killer cells in asthma pathogenesis: natural killer 2 cells in type 2 cytokine predominance. J Allergy Clin Immunol (2005) 115:841-7. doi:10.1016/j.jaci.2004.11.026.
162. Yu G, Xu X, Vu MD, Kilpatrick ED, Li XC. NK cells promote transplant tolerance by killing donor antigen-presenting cells. J Exp Med (2006) 203:1851-8. doi:10.1084/jem.20060603.
163. Spits H, Di Santo JP. The expanding family of innate lymphoid cells: regulators and effectors of immunity and tissue remodeling. Nat Immunol (2011) 12:21-7. doi:10.1038/ni.1962.
164. Takayama T, Kamada N, Chinen H, Okamoto S, Kitazume MT, Chang J, et al. Imbalance of NKp44(+)NKp46(-) and NKp44(-)NKp46(+) natural killer cells in the intestinal mucosa of patients with Crohn's disease. Gastroenterology (2010) 139:.e1-3. doi:10.1053/j.gastro.2010.05.040.
165. Shea JJ, Paul WE. Mechanisms underlying lineage commitment and plasticity of helper CD4+ T cells. Science (2010) 327:1098-102. doi:10.1126/science.1178334.
166. Magombedze G, Reddy PB, Eda S, Ganusov VV. Cellular and population plasticity of helper CD4(+) T cell responses. Front Physiol (2013) 4:206. doi:10.3389/fphys.2013.00206.
167. Wood KJ, Bushell A, Jones ND. Immunologic unresponsiveness to alloantigen in vivo: a role for regulatory T cells. Immunol Rev (2011) 241:119-32. doi:10.1111/j.1600065X.2011.01013.x.
168. Holm SJ, Sakuraba K, Mallbris L, Wolk K, Ståhle M, Sánchez FO. Distinct HLA-C/KIR genotype profile associates with guttate psoriasis. J Invest Dermatol (2005) 125:721-30. doi:10.1111/j.0022-202X.2005.23879.x.
169. Williams F, Meenagh A, Sleator C, Cook D, Fernandez-Vina M, Bowcock AM, et al. Activating killer cell immunoglobulin-like receptor gene KIR2DS1 is associated with psoriatic arthritis. Hum Immunol (2005) 66:836-41. doi:10.1016/j.humimm.2005.04.005.
170. Płoski R, Luszczek W, Kusnierczyk P, Nockowski P, Cisło M, Krajewski P, et al. A role for KIR gene variants other than KIR2DS1 in conferring susceptibility to psoriasis. Hum Immunol (2006) 67:521-6. doi:10.1016/j.humimm.2006.04.001.
171. Yen JH, Lin CH, Tsai WC, Wu CC, Ou TT, Hu CJ, et al. Killer cell immunoglobulin-like receptor gene's repertoire in rheumatoid arthritis. Scand J Rheumatol (2006) 35:124-7. doi:10.1080/03009740500381252.
172. Hou YF, Zhang YC, Jiao YL, Wang LC, Li JF, Pan ZL, et al. Disparate distribution of activating and inhibitory killer cell immunoglobulin-like receptor genes in patients with systemic lupus erythematosus. Lupus (2010) 19:20-6. doi:10.1177/0961203309345779.
173. Petukhova L, Duvic M, Hordinsky M, Norris D, Price V, Shimomura Y, et al. Genome-wide association study in alopecia areata implicates both innate and adaptive immunity. Nature (2010) 466:113-7. doi:10.1038/nature09114.
174. Jelcic I, Hsu KC, Kakalacheva K, Breiden P, Dupont B, Uhrberg M, et al. Killer immunoglobulin-like receptor locus polymorphisms in multiple sclerosis. Mult Scler (2012) 18:951-8. doi:10.1177/1352458511431726.
175. Ramírez-De los Santos S, Sánchez-Hernández PE, Muñoz-Valle JF, Palafox-Sánchez CA, Rosales-Rivera LY, García-Iglesias T, et al. Associations of killer cell immunoglobulin-like receptor genes with rheumatoid arthritis. Dis Markers (2012) 33:201-6. doi:10.3233/DMA-2012-0927.
176. Kusnierczyk P. Killer cell immunoglobulin-like receptor gene associations with autoimmune and allergic diseases, recurrent spontaneous abortion, and neoplasms. Front Immunol (2013) 4:8. doi:10.3389/fimmu.2013.00008.
177. Park KS, Park JH, Song YW. Inhibitory NKG2A and activating NKG2D and NKG2C natural killer cell receptor genes: susceptibility for rheumatoid arthritis. Tissue Antigens (2008) 72:342-6. doi:10.1111/j.1399-0039.2008.01110.x.
178. Chandran V, Bull SB, Pellett FJ, Ayearst R, Pollock RA, Gladman DD. Killer-cell immunoglobulin-like receptor gene polymorphisms and susceptibility to psoriatic arthritis. Rheumatology (Oxford) (2014) 53(2):233-9. doi:10.1093/rheumatology/ket296.
179. Chewning JH, Gudme CN, Hsu KC, Selvakumar A, Dupont B. KIR2DS1-positive NK cells mediate alloresponse against the C2 HLA-KIR ligand group in vitro. J Immunol (2007) 179:854-68.
180. Foley B, De Santis D, Lathbury L, Christiansen F, Witt C. KIR2DS1-mediated activation overrides NKG2A-mediated inhibition in HLA-C C2-negative individuals. Int Immunol (2008) 20:555-63. doi:10.1093/intimm/dxn013.
181. Sivori S, Carlomagno S, Falco M, Romeo E, Moretta L, Moretta A. Natural killer cells expressing the KIR2DS1-activating receptor efficiently kill T-cell blasts and dendritic cells: implications in haploidentical HSCT. Blood (2011) 117:4284-92. doi:10.1182/blood-2010-10-316125.
182. Venstrom JM, Pittari G, Gooley TA, Chewning JH, Spellman S, Haagenson M, et al. HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1. N Engl J Med (2012) 367:805-16. doi:10.1056/NEJMoa1200503.
183. Ouyang W. Distinct roles of IL-22 in human psoriasis and inflammatory bowel disease. Cytokine Growth Factor Rev (2010) 21:435-41. doi:10.1016/j.cytogfr.2010.10.007.
184. Dunphy S, Gardiner CM. NK cells and psoriasis. J Biomed Biotechnol (2011) 2011:248317. doi:10.1155/2011/248317.
185. McAleer JP, Kolls JK. Mechanisms controlling Th17 cytokine expression and host defense. J Leukoc Biol (2011) 90:263-70. doi:10.1189/jlb.0211099.
186. Wolk K, Witte E, Warszawska K, Schulze-Tanzil G, Witte K, Philipp S, et al. The Th17 cytokine IL-22 induces IL-20 production in keratinocytes: a novel immunological cascade with potential relevance in psoriasis. Eur J Immunol (2009) 39:3570-81. doi:10.1002/eji.200939687.
187. Nograles KE, Zaba LC, Guttman-Yassky E, Fuentes-Duculan J, Suárez-Fariñas M, Cardinale I, et al. Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol (2008) 159:1092-102. doi:10.1111/j.1365-2133.2008.08769.x.
188. Patel F, Marusina AI, Duong C, Adamopoulos IE, Maverakis E. NKG2C, HLA-E and their association with psoriasis. Exp Dermatol (2013) 22:797-9. doi:10.1111/exd.12280.
189. Zeng X, Chen H, Gupta R, Paz-Altschul O, Bowcock AM, Liao W. Deletion of the activating NKG2C receptor and a functional polymorphism in its ligand HLA-E in psoriasis susceptibility. Exp Dermatol (2013) 22:679-81. doi:10.1111/exd.12233.
190. Takahashi H, Amagai M, Tanikawa A, Suzuki S, Ikeda Y, Nishikawa T, et al. T helper type 2-biased natural killer cell phenotype in patients with pemphigus vulgaris. J Invest Dermatol (2007) 127:324-30. doi:10.1038/sj.jid.5700527.
191. Stern JN, Keskin DB, Barteneva N, Zuniga J, Yunis EJ, Ahmed AR. Possible role of natural killer cells in pemphigus vulgaris-preliminary observations. Clin Exp Immunol (2008) 152:472-81. doi:10.1111/j.1365-2249.2008.03638.x.
192. Benczur M, Petrányl GG, Pálffy G, Varga M, Tálas M, Kotsy B, et al. Dysfunction of natural killer cells in multiple sclerosis: a possible pathogenetic factor. Clin Exp Immunol (1980) 39:657-62.
193. Kastrukoff LF, Lau A, Wee R, Zecchini D, Whit R, Paty DW. Clinical relapses of multiple sclerosis are associated with 'novel' valleys in natural killer cell functional activity. J Neuroimmunol (2003) 145:103-14. doi:10.1016/j.jneuroim.2003.10.001.
194. Saraste M, Irjala H, Airas L. Expansion of CD56Bright natural killer cells in the peripheral blood of multiple sclerosis patients treated with interferon-beta. Neurol Sci (2007) 28:121-6. doi:10.1007/s10072-007-0803-3.
195. Bielekova B, Catalfamo M, Reichert-Scrivner S, Packer A, Cerna M, Waldmann TA, et al. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci U S A (2006) 103:5941-6. doi:10.1073/pnas.0601335103.
196. Bielekova B, Howard T, Packer AN, Richert N, Blevins G, Ohayon J, et al. Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. Arch Neurol (2009) 66:483-9. doi:10.1001/archneurol.2009.50.
197. Takahashi K, Miyake S, Kondo T, Terao K, Hatakenaka M, Hashimoto S, et al. Natural killer type 2 bias in remission of multiple sclerosis. J Clin Invest (2001) 107:R23-9. doi:10.1172/JCI11819.
198. Takahashi K, Aranami T, Endoh M, Miyake S, Yamamura T. The regulatory role of natural killer cells in multiple sclerosis. Brain (2004) 127:1917-27. doi:10.1093/brain/awh219.
199. Rodacki M, Svoren B, Butty V, Besse W, Laffel L, Benoist C, et al. Altered natural killer cells in type 1 diabetic patients. Diabetes (2007) 56:177-85. doi:10.2337/db06-0493.
200. Dotta F, Censini S, van Halteren AG, Marselli L, Masini M, Dionisi S, et al. Coxsackie B4 virus infection of beta cells and natural killer cell insulitis in recent-onset type 1 diabetic patients. Proc Natl Acad Sci U S A (2007) 104:5115-20. doi:10.1073/pnas.0700442104.
201. Willcox A, Richardson SJ, Bone AJ, Foulis AK, Morgan NG. Analysis of islet inflammation in human type 1 diabetes. Clin Exp Immunol (2009) 155:173-81. doi:10.1111/j.1365-2249.2008.03860.x.
202. Zhou M, McPherson L, Feng D, Song A, Dong C, Lyu SC, et al. Kruppel-like transcription factor 13 regulates T lymphocyte survival in vivo. J Immunol (2007) 178:5496-504.
203. Chen Y, Hu Y, Zhou T, Zhou KK, Mott R, Wu M, et al. Activation of the Wnt pathway plays a pathogenic role in diabetic retinopathy in humans and animal models. Am J Pathol (2009) 175:2676-85. doi:10.2353/ajpath.2009.080945.
204. Perricone R, Perricone C, De Carolis C, Shoenfeld Y. NK cells in autoimmunity: a two-edg'd weapon of the immune system. Autoimmun Rev (2008) 7:384-90. doi:10.1016/j.autrev.2008.03.002.
205. Kanai T, Mikami Y, Sujino T, Hisamatsu T, Hibi T. RORγt-dependent IL-17A-producing cells in the pathogenesis of intestinal inflammation. Mucosal Immunol (2012) 5:240-7. doi:10.1038/mi.2012.6.
206. Geremia A, Arancibia-Cárcamo CV, Fleming MP, Rust N, Singh B, Mortensen NJ, et al. IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease. J Exp Med (2011) 208(6):1127-33. doi:10.1084/jem.20101712.
207. Hudspeth K, Pontarini E, Tentorio P, Cimino M, Donadon M, Torzilli G, et al. The role of natural killer cells in autoimmune liver disease: a comprehensive review. J Autoimmun (2013) 46:55-65. doi:10.1016/j.jaut.2013.07.003.
208. Strassburg CP, Obermayer-Straub P, Manns MP. Autoimmunity in liver diseases. Clin Rev Allergy Immunol (2000) 18:127-39. doi:10.1385/CRIAI:18:2:127.
209. Oo YH, Hubscher SG, Adams DH. Autoimmune hepatitis: new paradigms in the pathogenesis, diagnosis, and management. Hepatol Int (2010) 4:475-93. doi:10.1007/s12072-010-9183-5.
210. Chen Y, Wei H, Gao B, Hu Z, Zheng S, Tian Z. Activation and function of hepatic NK cells in hepatitis B infection: an underinvestigated innate immune response. J Viral Hepat (2005) 12:38-45. doi:10.1111/j.1365-2893.2005.00543.x.
211. Harada K, Shimoda S, Sato Y, Isse K, Ikeda H, Nakanuma Y. Periductal interleukin-17 production in association with biliary innate immunity contributes to the pathogenesis of cholangiopathy in primary biliary cirrhosis. Clin Exp Immunol (2009) 157:261-70. doi:10.1111/j.1365-2249.2009.03947.x.
212. Shimoda S, Harada K, Niiro H, Shirabe K, Taketomi A, Maehara Y, et al. Interaction between Toll-like receptors and natural killer cells in the destruction of bile ducts in primary biliary cirrhosis. Hepatology (2011) 53(4):1270-81. doi:10.1002/hep.24194.
213. Shimoda S, Tsuneyama K, Kikuchi K, Harada K, Nakanuma Y, Nakamura M, et al. The role of natural killer (NK) and NK T cells in the loss of tolerance in murine primary biliary cirrhosis. Clin Exp Immunol (2012) 168:279-84. doi:10.1111/j.1365-2249.2012.04581.x.
214. Karlsen TH, Boberg KM, Olsson M, Sun JY, Senitzer D, Bergquist A, et al. Particular genetic variants of ligands for natural killer cell receptors may contribute to the HLA associated risk of primary sclerosing cholangitis. J Hepatol (2007) 46:899-906. doi:10.1016/j.jhep.2007.01.032.
215. Van Steenbergen W, De Goede E, Emonds MP, Reinders J, Tilanus M, Fevery J. Primary sclerosing cholangitis in two brothers: report of a family with special emphasis on molecular HLA and MICA genotyping. Eur J Gastroenterol Hepatol (2005) 17:767-71. doi:10.1097/00042737-200507000-00013.
216. Riccieri V, Spadaro A, Parisi G, Taccari E, Moretti T, Bernardini G, et al. Down-regulation of natural killer cells and of gamma/delta T cells in systemic lupus erythematosus. Does it correlate to autoimmunity and to laboratory indices of disease activity? Lupus (2000) 9:333-7. doi:10.1191/096120300678828460.
217. Toyabe S, Kaneko U, Uchiyama M. Decreased DAP12 expression in natural killer lymphocytes from patients with systemic lupus erythematosus is associated with increased transcript mutations. J Autoimmun (2004) 23:371-8. doi:10.1016/j.jaut.2004.09.003.
218. Green MR, Kennell AS, Larche MJ, Seifert MH, Isenberg DA, Salaman MR. Natural killer cell activity in families of patients with systemic lupus erythematosus: demonstration of a killing defect in patients. Clin Exp Immunol (2005) 14:165-73. doi:10.1111/j.1365-2249.2009.03938.x.
219. Park YW, Kee SJ, Cho YN, Lee EH, Lee HY, Kim EM, et al. Impaired differentiation and cytotoxicity of natural killer cells in systemic lupus erythematosus. Arthritis Rheum (2009) 60:1753-63. doi:10.1002/art.24556.
220. Hervier B, Beziat V, Haroche J, Mathian A, Lebon P, Ghillani-Dalbin P, et al. Phenotype and function of natural killer cells in systemic lupus erythematosus: excess interferon-γ production in patients with active disease. Arthritis Rheum (2011) 63:1698-706. doi:10.1002/art.30313.
221. Abud-Mendoza C, Cuevas-Orta E, Santillán-Guerrero EN, Martínez-Martínez MU, Hernández-Castro B, Estrada-Capetillo L, et al. Decreased blood levels of B lymphocytes and NK cells in patients with systemic lupus erythematosus (SLE) infected with papillomavirus (HPV). Arch Dermatol Res (2013) 305:117-23. doi:10.1007/s00403-012-1258-9.
222. Henriques A, Teixeira L, Inês L, Carvalheiro T, Gonçalves A, Martinho A, et al. NK cells dysfunction in systemic lupus erythematosus: relation to disease activity. Clin Rheumatol (2013) 32:805-13. doi:10.1007/s10067-013-2176-8.
223. Schepis D, Gunnarsson I, Eloranta ML, Lampa J, Jacobson SH, Kärre K, et al. Increased proportion of CD56bright natural killer cells in active and inactive systemic lupus erythematosus. Immunology (2009) 126:140-6. doi:10.1111/j.1365-2567.2008.02887.x.
224. Puxeddu I, Bongiorni F, Chimenti D, Bombardieri S, Moretta A, Bottino C, et al. Cell surface expression of activating receptors and co-receptors on peripheral blood NK cells in systemic autoimmune diseases. Scand J Rheumatol (2012) 41:298-304. doi:10.3109/03009742.2011.648657.
225. Hagberg N, Theorell J, Eloranta ML, Pascal V, Bryceson YT, Rönnblom L. Anti-NKG2A autoantibodies in a patient with systemic lupus erythematosus. Rheumatology (Oxford) (2013) 52:1818-23. doi:10.1093/rheumatology/ket220.
226. Hagberg N, Theorell J, Schlums H, Eloranta ML, Bryceson YT, Rönnblom L. Systemic lupus erythematosus immune complexes increase the expression of SLAM family members CD319 (CRACC) and CD229 (LY-9) on plasmacytoid dendritic cells and CD319 on CD56(dim) NK cells. J Immunol (2013) 191:2989-98. doi:10.4049/jimmunol.1301022.
227. Kim JR, Mathew SO, Patel RK, Pertusi RM, Mathew PA. Altered expression of signalling lymphocyte activation molecule (SLAM) family receptors CS1 (CD319) and 2B4 (CD244) in patients with systemic lupus erythematosus. Clin Exp Immunol (2010) 160:348-58. doi:10.1111/j.1365-2249.2010.04116.x.